The FLX treatment significantly decreased the ratios of oligodendrocytes expressing p16 in the CA2-3 fields and DG of AD mice (59.30 ± 18.67% in the CA2-3 fields and 56.45 ± 17.80% in the DG; p = 0.018 and p = 0.024, respectively; Figure 4F). Here, CDKN2A is linked to Alzheimer disease.